1,721,392 research outputs found
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group.
No full textBIOLOGIC THERAPY IN INFLAMMATORY AND IMMUNOMEDIATED ARTHRITIS: SAFETY PROFILE
No full textThe increasing insights into the pathogenetic mechanisms of inflammatory autoimmune arthritis and the development of innovative systems of industrial production have led to discover molecules which are targeted at molecules involved in the mechanisms of the immune system and that have been introduced in clinical practice to provide an alternative to the existing treatment methods of disease-modifying anti-rheumatic drugs and other immunosuppressive medications. For this reason, such drugs are currently known as "biological drugs" and include molecules that induce the immunosuppression acting on several immune pathways. However, though the biological drugs have been employed from more than a decade, there still exist some drawbacks of their use, including the inconvenience of intravenous administration, the high costs, and adverse events associated with them. This review provides an update on the correct use and current therapeutic indications of such drugs, including some of the new biologic therapies that will be soon available for the clinical use, focusing on these biological drugs: tumor necrosis factor (TNF) inhibitors (adalimumab, certolizumab-pegol, etanercept, golimumab and infliximab); the T cell co-stimulation inhibitor, abatacept; the anti-CD20 receptor monoclonal B cell agent, rituximab; the IL-6 receptor-blocking monoclonal antibody, tocilizumab; the IL-1-inhibitor, anakinra; the IL-17-pathway inhibitors (ustekinumab, secukinumab, brodalumab)
Management of minor head injury in patients receiving oral anticoagulant therapy: a prospective study of a 24-hour observation protocol.
No full text
Potential Anti-Tumor Activity of Intravenous and Subcutaneous Immunoglobulin
Full text linkThis case study and brief review shows that IVIg can have an inhibitory role on growth and tumor spread in both solid neoplasms and lymphoproliferative diseases. Various molecular and cellular pathways are involved in this fight against tumor growth and spread, although the specific manifestations are not completely understood. There are no available data on SCIg and cancer. It is thus possible that the administration of IVIg supplemented with SCIg can help in the treatment of cancer itself and its metastases. More experimental and clinical data are necessary to confirm these preliminary observations
- …
